https://www.selleckchem.com/products/bi-4020.html
warfarin users were doubling SCr, 0.63 (0.49-0.81); ≥30% decline in eGFR, 0.76 (0.67-0.86); ESRD, 0.77 (0.29-2.04). Similar results were observed among patients with diabetes or heart failure. Estimated mean decline in renal function over the study period was 2.03ml/min/1.73m /year among warfarin users and 1.65ml/min/1.73m /year among rivaroxaban users (p=0.03). We found clear evidence that patients with NVAF, preserved renal function at baseline and treated with rivaroxaban had a markedly reduced risk and rate of renal decline compared
Like
Comment
Share
